Clinical Trial Update: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of tovorafenib (DAY101) as a potential treatment for progressive, relapsed, or refractory Langerhans cell h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Langerhans Cell Histiocytosis

Drugs mentioned

• Tovorafenib (DAY101) (tovorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis | Phase 2 | Status: RECRUITING